Literature DB >> 21182230

Role of serotonin in development of esophageal and gastric fundal varices.

Jelena S Rudić1, Dorđe M Culafić, Duško S Mirković, Rada S Ješić, Miodrag N Krstić.   

Abstract

AIM: to determine the effect of free serotonin concentrations in plasma on development of esophageal and gastric fundal varices.
METHODS: this prospective study included 33 patients with liver cirrhosis and 24 healthy controls. Ultrasonography and measurement of serotonin concentration in plasma were carried out in both groups of subjects. The upper fiber panendoscopy was performed only in patients with liver cirrhosis.
RESULTS: the mean plasma free serotonin levels were much higher in liver cirrhosis patients than in healthy controls (219.0 ± 24.2 nmol/L vs 65.4 ± 18.7 nmol/L, P < 0.0001). There was no significant correlation between serotonin concentration in plasma and the size of the esophageal varices according to Spearman coefficient of correlation (r(s) = -0.217, P > 0.05). However, the correlation of plasma serotonin concentration and gastric fundal varices was highly significant (r(s) = -0.601, P < 0.01).
CONCLUSION: free serotonin is significant in pathogenesis of portal hypertension especially in development of fundal varices, indicating the clinical value of serotonergic receptor blockers in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21182230      PMCID: PMC3012586          DOI: 10.3748/wjg.v16.i48.6135

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

Review 1.  [Left-side portal hypertension as a clinical problem].

Authors:  D Zadrozny
Journal:  Wiad Lek       Date:  1999

2.  Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation.

Authors:  G Laffi; F Marra; P Gresele; P Romagnoli; A Palermo; O Bartolini; A Simoni; L Orlandi; M L Selli; G G Nenci
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

3.  Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis.

Authors:  Erawan Borkham-Kamphorst; Jens Herrmann; Doris Stoll; Jens Treptau; Axel M Gressner; Ralf Weiskirchen
Journal:  Lab Invest       Date:  2004-06       Impact factor: 5.662

4.  Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients.

Authors:  J Vorobioff; G Garcia-Tsao; R Groszmann; G Aceves; E Picabea; R Villavicencio; J Hernandez-Ortiz
Journal:  Hepatology       Date:  1989-01       Impact factor: 17.425

5.  Evaluation of splenomegaly in portal hypertension.

Authors:  S G Sheth; D N Amarapurkar; K B Chopra; S A Mani; P J Mehta
Journal:  J Clin Gastroenterol       Date:  1996-01       Impact factor: 3.062

6.  Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis.

Authors:  A B Lumsden; J M Henderson; M H Kutner
Journal:  Hepatology       Date:  1988 Mar-Apr       Impact factor: 17.425

7.  Splenic haemodynamics and portal hypertension in patients with liver cirrhosis and spleen enlargement.

Authors:  C Merkel; A Gatta; L Arnaboldi; R Zuin
Journal:  Clin Physiol       Date:  1985-12

Review 8.  The function of serotonin within the liver.

Authors:  Richard G Ruddell; Derek A Mann; Grant A Ramm
Journal:  J Hepatol       Date:  2008-01-28       Impact factor: 25.083

9.  Hepatic fibrogenesis requires sympathetic neurotransmitters.

Authors:  J A Oben; T Roskams; S Yang; H Lin; N Sinelli; M Torbenson; U Smedh; T H Moran; Z Li; J Huang; S A Thomas; A M Diehl
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

10.  Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis.

Authors:  P Beaudry; A Hadengue; J Callebert; C Gaudin; H Soliman; R Moreau; J M Launay; D Lebrec
Journal:  Hepatology       Date:  1994-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.